PRESS RELEASES

All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this study Robust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentration

DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2

Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association

Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation

DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion,

DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dale Schenk, PhD, the Company's President

Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with

Entering clinic triggers $15 million milestone payment from Roche DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential

NEOD001 Enters Clinic With Orphan Designation and Potential to Meet Significant Unmet Need

Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders